MedTrace Logo

The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

NCT00964093 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether silver alginate (Algidex) patch is effective in the prevention of central line infections in very low birth weight infants.

Conditions

  • Central Line Bloodstream Infections

Interventions

DEVICE

Silver Alginate

(Algidex ™)

Sponsors & Collaborators

  • DeRoyal Industries, Inc.

    collaborator INDUSTRY

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • Asif Khattak, MD · Baylor Health Care System

  • David M Kanter, MD · St. Mary's Medical Center, West Palm Beach, FL

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
3 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-23
Primary Completion
2014-08-25
Completion
2015-08-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00964093 on ClinicalTrials.gov